This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrough so advanced, it’s going to make ChatGPT look like VHS. But what’s even more unbelievable? I believe it’ll make Nvidia’s meteoric rise look like a backyard bottle rocket.

Click here and I’ll tell you everything you need to know.

Adam Crystal Biography and Net Worth

Insider of C4 Therapeutics

Adam Crystal, M.D., Ph.D. joined C4 Therapeutics in February 2019 as our Chief Medical Officer. Previously, Adam was at Novartis Institutes for Biomedical Research, most recently as Senior Director, where he led several early clinical development programs. Before transitioning to industry, Adam was a medical oncologist at Massachusetts General Hospital where he researched resistance mechanisms to targeted therapies. Adam was also a laboratory-based researcher at Massachusetts General Hospital where his work on resistance mechanisms to targeted therapies was recognized with the American Society of Clinical Oncology Conquer Cancer Young Investigator Award and was also published in Science. He trained at Massachusetts General Hospital in internal medicine, and in medical oncology at the Massachusetts General Hospital Cancer Center and the Dana-Farber Cancer Institute. Adam holds an M.D., as well as a Ph.D. in Neuroscience from the University of Pennsylvania School of Medicine.

What is Adam Crystal's net worth?: The estimated net worth of Adam Crystal is at least $486,830.34 as of February 6th, 2024. Dr. Crystal owns 123,561 shares of C4 Therapeutics stock worth more than $486,830 as of November 21st. This net worth estimate does not reflect any other assets that Dr. Crystal may own. Learn More about Adam Crystal's net worth.
How do I contact Adam Crystal?: The corporate mailing address for Dr. Crystal and other C4 Therapeutics executives is , , . C4 Therapeutics can also be reached via phone at 617-231-0700 and via email at [email protected]. Learn More on Adam Crystal's contact information.
Has Adam Crystal been buying or selling shares of C4 Therapeutics?: Adam Crystal has not been actively trading shares of C4 Therapeutics over the course of the past ninety days. Most recently, Adam Crystal sold 15,000 shares of the business's stock in a transaction on Friday, October 1st. The shares were sold at an average price of $45.43, for a transaction totalling $681,450.00. Learn More on Adam Crystal's trading history.
Who are C4 Therapeutics' active insiders?: C4 Therapeutics' insider roster includes Adam Crystal (Insider), Stewart Fisher (Insider), Elena Prokupets (Director), Malcolm Salter (Director), and Jolie Siegel (Insider). Learn More on C4 Therapeutics' active insiders.

Adam Crystal Insider Trading History at C4 Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/1/2021	Sell	15,000	$45.43	$681,450.00
7/1/2021	Sell	15,000	$37.98	$569,700.00	15,000
4/5/2021	Sell	15,000	$37.77	$566,550.00	15,000

Adam Crystal Buying and Selling Activity at C4 Therapeutics

C4 Therapeutics Company Overview

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Today's Range

Now: $3.94

$3.94

$4.09

50 Day Range

MA: $5.77

$4.05

$7.00

2 Week Range

Now: $3.94

$1.06

$11.88

Volume

48,274 shs

Average Volume

2,104,853 shs

Market Capitalization

$278.12 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.04

Urgent: This election is rigged

From Porter & Company | Ad

If you missed it, my emergency election broadcast is now available - but will be removed soon

Click here to watch it now.